Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Adaptive Biotechnologies

Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference

Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc

Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum. Shares are up 250% in the past year and just hit a new three-year high. ADPT maintains a 100% “Buy” opinion from Barchart, a Trend Seeker “Buy” signal, and robust technical indicators. Fundamentals show projected revenue and earnings growth,...

Is Cathie Wood Cashing Out? Ark CEO Dumps Millions in Biopharma and Aviation Stocks

Is Cathie Wood Cashing Out? Ark CEO Dumps Millions in Biopharma and Aviation Stocks

Cathie Wood aggressively sold shares of Adaptive Biotechnologies, Veracyte, and Archer Aviation on 31st May, according to a 6th June filing with the SEC.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022

Why Adaptive Biotechnologies Shares Are Rising

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80 million.

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine.

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36 million.

Recap: Adaptive Biotechnologies Q4 Earnings

Recap: Adaptive Biotechnologies Q4 Earnings

Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Micron Technology

B of A Securities

Archer Aviation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

391,917 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play